[EMPLOYMENT AGREEMENT Agreement Executive Company This EMPLOYMENT AGREEMENT (this “ WHEREAS, the Company desires to employ Executive as its Chief Financial Officer on the terms and conditions as set forth hereinafter, and Executive desires to be so employed; NOW, THEREFORE, IN CONSIDERATION of the foregoing facts, the mutual covenants and agreements contained herein and other good and valuable consideration, the] [SKYSTAR APPOINTS NEW CHIEF FINANCIAL OFFICER Bing Mei to join as CFO XI'AN, CHINA – August 1, 2011 - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Mr. Mei, is a seasoned chief financial officer fluent in both English and Mandarin with over 20 years of diverse industry experience including technology services and industrial manufacturing businesses and successful track record]

[EMPLOYMENTREEMENTreement Executivempany This EMPLOYMENTREEMENT (this WHEREAS, thempany desires to employ Executive its Chief Financial Officer on the terms andnditions set forth hereinafter, and Executive desires to be so employed; NOW, THEREFORE, INNSIDERATION of the foregoing facts, the mutualvenants andreementsntained herein and other good and valuablensideration, the parties herebyree follows:] [SKYSTAR APPOINTS NEW CHIEF FINANCIAL OFFICER Bing Mei to join CFO XI'AN, CHINA August 1, 2011 -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), Mr. Mei, is a seasoned chief financial officer fluent in both English and Mandarin with over 20 years of diverse industry experienceluding technology services and industrial manufacturing businesses and successful track record]

[NEWS RELEASE Skystar Bio-Pharmaceutical Reports First Quarter 2011 Results $7.0 Million Top Line; $0.27 Diluted EPS; Reiterates Fiscal 2011 Top Line Guidance range of $60 Million to $63 Million “ ” “ ” XI’AN, CHINA – May 23, 2011 -- Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ( First Quarter 2011 Highlights · Revenue increases 46% YoY to $7.0 million · Veterinary vaccines]

[NEWS RELEASEystar Bio-Pharmaceutical Reports First Quarter 2011 Results $7.0 Million Top Line; $0.27 Diluted EPS; Reiterates Fiscal 2011 Top Line Guidance range of $60 Million to $63 Million XIAN, CHINA May 23, 2011 --Skystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ( First Quarter 2011 Highlights Revenuereases 46% YoY to $7.0 million Veterinary vaccines totaled $0.3 million, up 30% YoY]